Table 5 Mexican launch dates of drugs used to treat different types of cancer
From: The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013
Cancer site | Drug | Launch year |
|---|---|---|
C00–C14 head and neck cancer | Docetaxel | 1995 |
C00–C14 head and neck cancer | Cetuximab | 2004 |
C15 esophageal cancer | Docetaxel | 1995 |
C15 esophageal cancer | Trastuzumab | 2000 |
C16 stomach (gastric) cancer | Docetaxel | 1995 |
C16 stomach (gastric) cancer | Trastuzumab | 2000 |
C18, C20 colon and rectal cancer | Irinotecan | 1998 |
C18, C20 colon and rectal cancer | Capecitabine | 2000 |
C18, C20 colon and rectal cancer | Oxaliplatin | 2002 |
C18, C20 colon and rectal cancer | Cetuximab | 2004 |
C18, C20 colon and rectal cancer | Bevacizumab | 2005 |
C18, C20 colon and rectal cancer | Panitumumab | 2011 |
C18, C20 colon and rectal cancer | Aflibercept | 2014 |
C25 pancreatic cancer | Paclitaxel | 1995 |
C25 pancreatic cancer | Gemcitabine | 1997 |
C25 pancreatic cancer | Irinotecan | 1998 |
C25 pancreatic cancer | Erlotinib | 2006 |
C25 pancreatic cancer | Everolimus | 2006 |
C25 pancreatic cancer | Sunitinib | 2006 |
C34 lung cancer | Carboplatin | 1992 |
C34 lung cancer | Docetaxel | 1995 |
C34 lung cancer | Paclitaxel | 1995 |
C34 lung cancer | Gemcitabine | 1997 |
C34 lung cancer | Vinorelbine | 1998 |
C34 lung cancer | Gefitinib | 2004 |
C34 lung cancer | Bevacizumab | 2005 |
C34 lung cancer | Pemetrexed | 2005 |
C34 lung cancer | Erlotinib | 2006 |
C34 lung cancer | Topotecan | 2008 |
C34 lung cancer | Crizotinib | 2012 |
C40–C41 bone cancer | Denosumab | 2012 |
C43 melanoma | Interferon alfa-2b | 1987 |
C43 melanoma | Aldesleukin | 1996 |
C43 melanoma | Peginterferon alfa-2b | 2001 |
C43 melanoma | Ipilimumab | 2012 |
C43 melanoma | Vemurafenib | 2012 |
C44 basal cell carcinoma | Imiquimod | 1999 |
C45 malignant mesothelioma | Pemetrexed | 2005 |
C46 kaposi sarcoma | Interferon alfa-2b | 1987 |
C46 kaposi sarcoma | Paclitaxel | 1995 |
C49 soft tissue sarcoma | Imatinib | 2001 |
C49 soft tissue sarcoma | Trabectedin | 2010 |
C49 soft tissue sarcoma | Pazopanib | 2012 |
C50 breast cancer | Epirubicin | 1987 |
C50 breast cancer | Goserelin | 1991 |
C50 breast cancer | Docetaxel | 1995 |
C50 breast cancer | Paclitaxel | 1995 |
C50 breast cancer | Gemcitabine | 1997 |
C50 breast cancer | Anastrozole | 1998 |
C50 breast cancer | Raloxifene | 1998 |
C50 breast cancer | Toremifene | 1999 |
C50 breast cancer | Capecitabine | 2000 |
C50 breast cancer | Letrozole | 2000 |
C50 breast cancer | Trastuzumab | 2000 |
C50 breast cancer | Exemestane | 2004 |
C50 breast cancer | Everolimus | 2006 |
C50 breast cancer | Fulvestrant | 2009 |
C50 breast cancer | Ixabepilone | 2009 |
C50 breast cancer | Lapatinib | 2009 |
C50 breast cancer | Trastuzumab emtansine | 2014 |
C53 cervical cancer | Bevacizumab | 2005 |
C53 cervical cancer | Topotecan | 2008 |
C56 ovarian, fallopian tube, or primary peritoneal cancer | Carboplatin | 1992 |
C56 ovarian, fallopian tube, or primary peritoneal cancer | Paclitaxel | 1995 |
C56 ovarian, fallopian tube, or primary peritoneal cancer | Gemcitabine | 1997 |
C56 ovarian, fallopian tube, or primary peritoneal cancer | Bevacizumab | 2005 |
C56 ovarian, fallopian tube, or primary peritoneal cancer | Topotecan | 2008 |
C61 prostate cancer | Flutamide | 1987 |
C61 prostate cancer | Mitoxantrone | 1987 |
C61 prostate cancer | Leuprorelin | 1989 |
C61 prostate cancer | Goserelin | 1991 |
C61 prostate cancer | Docetaxel | 1995 |
C61 prostate cancer | Bicalutamide | 1997 |
C61 prostate cancer | Degarelix | 2010 |
C61 prostate cancer | Cabazitaxel | 2012 |
C64–C65 kidney (renal cell) cancer | Aldesleukin | 1996 |
C64–C65 kidney (renal cell) cancer | Bevacizumab | 2005 |
C64–C65 kidney (renal cell) cancer | Everolimus | 2006 |
C64–C65 kidney (renal cell) cancer | Sunitinib | 2006 |
C64–C65 kidney (renal cell) cancer | Temsirolimus | 2011 |
C64–C65 kidney (renal cell) cancer | Pazopanib | 2012 |
C71 brain tumors | Temozolomide | 1999 |
C71 brain tumors | Bevacizumab | 2005 |
C71 brain tumors | Everolimus | 2006 |
C73 thyroid cancer | Vandetanib | 2014 |
C81 hodgkin lymphoma | Brentuximab vedotin | 2014 |
C82–C85 non-hodgkin lymphoma | Interferon alfa-2b | 1987 |
C82–C85 non-hodgkin lymphoma | Rituximab | 1999 |
C82–C85 non-hodgkin lymphoma | Bortezomib | 2006 |
C82–C85 non-hodgkin lymphoma | Lenalidomide | 2008 |
C82–C85 non-hodgkin lymphoma | Plerixafor | 2009 |
C82–C85 non-hodgkin lymphoma | Brentuximab vedotin | 2014 |
C90 multiple myeloma and other plasma cell neoplasms | Zoledronic acid | 2001 |
C90 multiple myeloma and other plasma cell neoplasms | Bortezomib | 2006 |
C90 multiple myeloma and other plasma cell neoplasms | Lenalidomide | 2008 |
C90 multiple myeloma and other plasma cell neoplasms | Plerixafor | 2009 |
C91, C92 leukemia | Interferon alfa-2b | 1987 |
C91, C92 leukemia | Mitoxantrone | 1987 |
C91, C92 leukemia | Idarubicin | 1992 |
C91, C92 leukemia | Rituximab | 1999 |
C91, C92 leukemia | Imatinib | 2001 |
C91, C92 leukemia | Dasatinib | 2007 |
C91, C92 leukemia | Nilotinib | 2007 |
C91, C92 leukemia | Clofarabine | 2009 |
C91, C92 leukemia | Obinutuzumab | 2014 |